Danish oncology firm TopoTarget A/S acquired UK cell cycle specialist Prolifix Ltd. in a combined cash and shares deal. The Copenhagen-based company also raised DKK120 million (US$15.3 million) in new funding, from HealthCap of Stockholm and BankInvest of Copenhagen. (BioWorld International)
Danish oncology firm TopoTarget A/S acquired UK cell cycle specialist Prolifix Ltd. in a combined cash and shares deal. The Copenhagen-based company also raised DKK120 million (US$15.3 million) in new funding, from HealthCap of Stockholm and BankInvest of Copenhagen. (BioWorld International)
